Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 12, 2011, Pages 1795-1803

  Simões, Camila C ^a   Call, Mindy K ^a   Corrêa, Zélia M ^a   Spaulding, Abbot G ^a   Augsburger, James J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Beta catenin; Histopathology; LZTS1; Melanoma; Metastasis; Osteopontin; Prognostic factors; Uveal melanoma; Vimentin

Indexed keywords

BETA CATENIN; CYTOKERATIN 18; CYTOKERATIN 8; FORMALDEHYDE; LEUCINE ZIPPER TUMOR SUPPRESSOR 1 PROTEIN; OSTEOPONTIN; PARAFFIN; PROTEIN ANTIBODY; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHOROID MELANOMA; CILIARY BODY TUMOR; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENUCLEATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CHOROID NEOPLASMS; CILIARY BODY; DNA-BINDING PROTEINS; EYE ENUCLEATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KERATIN-18; KERATIN-8; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; OSTEOPONTIN; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VIMENTIN;

EID: 84856251299     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1769-7     Document Type: Article

References (44)

1. Mooy CM, De Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41(3):215-228 (Pubitemid 26424326)
2. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110(5):956-961 (Pubitemid 36560496)
3. Kujala E, Makitie T, Kivelä T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44(11):4651-4659 (Pubitemid 37315273)
4. Gilson MM, Diener-West M, Hawkins BS (2007) Comparison of survival among eligible patients not enrolled versus enrolled in the Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. COMS report number 24. Ophthalmic Epidemiol 14(4):251-7 (Pubitemid 47493730)
5. Callender GR (1931) Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 36:131-142
6. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched casecontrol study. Hum Pathol 23(11):1298-1305
7. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100(9):1389-1398 (Pubitemid 23274035)
8. McLean IW, Keefe KS, Burnier MN (1997) Uveal melanoma: comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type and tumor size. Ophthalmology 104(5):777-780 (Pubitemid 27200874)
9. Makitie T, Summanen P, Tarkannen A, Kivelä T (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91(4):359-367 (Pubitemid 29102336)
10. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222-1225 (Pubitemid 26131850)
11. Sisley K, Rennie IG, Parsons MA, Jacques R, HammondDW, Bell SM, Potter AM, Rees RC (1997) Abnormalities of chromosome 3 and 8 in posterior uveal melanoma correlate with prognosis. Gene Chromosomes Cancer 19(1):22-28 (Pubitemid 27193716)
12. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE (1998) Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83(2):354-359 (Pubitemid 28317816)
13. Naus NC, Van Drunen E, de Klein A, Luyten GP, Paridaens DA, Alers JC, Ksander BR, Beverloo HB, Slater RM (2001) Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karotyping, and comparative genomic hybridization. Genes Chromosomes Cancer 30(3):267-273 (Pubitemid 32126203)
14. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK (2003) Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 44(3):1008-1011 (Pubitemid 36297813)
15. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64(20):7205-7209 (Pubitemid 39372052)
16. Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, Perry A, Harbour JW (2007) Transcriptonic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 13(5):1466-1471 (Pubitemid 46450436)
17. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L,Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe'er J (2006) Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47(3):802-806 (Pubitemid 46768309)
18. Fuchs U, Kivelä T, Summanen P, Immonen I, Tarkkanen A (1992) An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 141 (1):169-181
19. Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R (1998) Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers. Lab Invest 78(2):153-163 (Pubitemid 28113454)
20. Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, Folberg R, Hendrix MJ (2002) Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 19(3):233-246 (Pubitemid 34553524)
21. Onken MD, Worley LA, Harbour JW (2008) A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res 14 (12):3737-3745
22. Chang SH, Worley LA, Onken MD, Harbour JW (2008) Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 18 (3):191-200 (Pubitemid 351684664)
23. Augsburger JJ, Corrêa ZM, Shaikh AH (2009) Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 148 (1):119-127
24. Standal T, Borset M, Sundan A (2004) Role of Osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26(3):179-184
25. Zhou YW, Dai DL, Martinka M et al (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124(5):1044-1052 (Pubitemid 40629107)
26. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90(10):1877-1881 (Pubitemid 38746324)
27. Barak V, Frenkel S, Kalickman I et al (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27(4A):1897-1900 (Pubitemid 46954694)
28. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC (2009) Osteopontin and melanoma inhibitory activity: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223(4):239-243
29. Kan-Mitchell J, Rao N, Albert DM, Van Eldik LJ, Taylor CR (1990) S100 immunophenotypes of uveal melanomas. Invest Ophthalmol Vis Sci 31(8):1492-1496 (Pubitemid 20265954)
30. Caselitz J, Jänner M, Breitbart E, Weber K, Osborn M (1983) Malignant melanomas contain only the vimentin type of intermediate filaments. Virchows Arch A Pathol Anat Histopathol 400 (1):43-51 (Pubitemid 13089120)
31. Ramaekers FC, Puts JJ, Moesker O, Kant A, Vooijs GP, Jap PH (1983) Intermediate filaments in malignant melanoma. Identification and use in surgical pathology. J Clin Invest 71(3):635-643 (Pubitemid 13160811)
32. Miettinen M, Franssila K (1989) Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest 61(6):623-628 (Pubitemid 20027689)
33. Pitz S, Moll R, Rochels R (1989) Intermediate filaments and melanoma markers in ocular malignant melanomas. An immunohistochemical and biochemical study. Abstracts of the International Symposium, Tumors of the Eye, Deutsche Ophthalmologische Gesellschaft, Essen, Germany, p23
34. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM (1999) The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 96(7):3928-3933 (Pubitemid 29169013)
35. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM (2001) FEZ1/LTZS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 98(18):10374-10379 (Pubitemid 32803027)
36. Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM, Baffa R (2001) FEZ1/LZTS1 alterations in gastric carcinoma. Clin Cancer Res 7(6):1546-1552 (Pubitemid 32708618)
37. Ono K, Uzawa K, Nakatsuru M, Shiiba M, Mochida Y, Tada A, Bukawa H, Miyakawa A, Yokoe H, Tanzawa H (2003) Downregulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinoma. Int J Oncol 23(2):297-302
38. Vecchione A, Croce CM, Baldassarre G (2007) FEZ1/LZTS1 a new mitotic regulator implicated in cancer development. Cell Div 2:24
39. Zuidervaart W, Pavey S, Van Nieuwpoort FA et al (2007) Expression of Wnt5a and its downstream effector β-catenin in uveal melanoma. Melanoma Res 17(6):380-386 (Pubitemid 350084993)
40. Silye R, Karayiannakis AJ, Syrigos KN, Poole S, van Noorden S, Batchelor W, Regele H, Sega W, Boesmueller H, Krausz T, Pignatelli M (1998) E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 186 (4):350-355 (Pubitemid 29005452)
41. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL (2003) Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 103(5):652-656 (Pubitemid 36091470)
42. Kim K, Pang KM, Evans M, Hay ED (2000) Overexpression of β-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 11(10):3509-3523
43. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW (2006) Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 66 (9):4602-4609
44. Kim K, Kj D, Hay ED (1998) Tissue-specific expression of betacatenin in normal mesenchyme and uveal melanomas and its effect on invasiveness. Exp Cell Res 245(1):79-90 (Pubitemid 28551057)